Effectiveness of Prophylactic Oral and/or Vaginal Probiotic Supplementation in the Prevention of Recurrent Urinary Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Trial

医学 安慰剂 益生菌 内科学 泌尿系统 安慰剂对照研究 抗生素 不利影响 胃肠病学 随机对照试验 临床试验 双盲 微生物学 细菌 病理 生物 替代医学 遗传学
作者
Varsha Gupta,Paola Mastromarino,Ritu Garg
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:78 (5): 1154-1161 被引量:31
标识
DOI:10.1093/cid/ciad766
摘要

Abstract Background Widespread antibiotic resistance has sparked interest in the identification of nonantibiotic strategies, particularly probiotics for the prevention of recurrent urinary tract infections (UTIs). We evaluated the effectiveness of prophylactic probiotic supplementation through oral and intravaginal routes in the prevention of recurrent UTIs. Methods This double-blind, placebo-controlled study enrolled 174 premenopausal women with a history of recurrent UTIs and randomized them to 1 of the 4 treatment groups: placebo (G1, oral placebo + vaginal placebo), oral probiotic (G2, oral lactic acid bacteria and bifidobacteria + vaginal placebo), vaginal probiotic (G3, oral placebo + vaginal lactobacilli), and probiotic combination (oral lactic acid bacteria and bifidobacteria + vaginal lactobacilli), for 4 months. Participants were followed up for symptomatic UTIs for 1 year. The primary end points were the number of symptomatic UTIs at 4 months, the proportion of participants with at least 1 symptomatic UTI, and the time to the first symptomatic UTI. Results The incidence of UTI at 4 months in G1, G2, G3, and G4 was 70.4%, 61.3%, 40.9%, and 31.8%, respectively. The mean number of symptomatic UTI recurrences at 4 months was significantly lower (P < .05) in G3 (1.06) and G4 (1.07) compared with G1 (2.1) and G2 (1.63). Further, the time to first symptomatic UTI (days) was significantly longer (P < .05) in G3 (123.8) and G4 (141.8) compared with G1 (69.3) and G2 (71.9). Probiotic supplementations were well tolerated with no serious adverse events. Conclusions Prophylactic supplementation with either vaginal probiotics or in combination with oral probiotics demonstrated effectiveness in preventing recurrent symptomatic UTI episodes. Clinical Trials Registration Registered at Clinical Trials Registry India (CTRI): CTRI/2014/02/004425 (https://ctri.nic.in).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhaomr完成签到,获得积分0
刚刚
梦想启航应助轻松的雨旋采纳,获得10
刚刚
汉堡包应助科研通管家采纳,获得10
2秒前
Moonpie应助科研通管家采纳,获得10
2秒前
Jasper应助科研通管家采纳,获得10
2秒前
Moonpie应助科研通管家采纳,获得10
2秒前
Ukiss完成签到 ,获得积分10
2秒前
无花果应助科研通管家采纳,获得10
3秒前
zhhua完成签到,获得积分10
3秒前
Moonpie应助科研通管家采纳,获得10
3秒前
CodeCraft应助科研通管家采纳,获得10
3秒前
3秒前
洁净大地应助科研通管家采纳,获得10
3秒前
汉堡包应助科研通管家采纳,获得10
3秒前
3秒前
Moonpie应助科研通管家采纳,获得10
3秒前
3秒前
orixero应助科研通管家采纳,获得10
3秒前
彭于晏应助科研通管家采纳,获得10
3秒前
淡定猎豹完成签到,获得积分10
3秒前
在水一方应助科研通管家采纳,获得10
3秒前
深情安青应助科研通管家采纳,获得10
3秒前
田様应助科研通管家采纳,获得10
3秒前
领导范儿应助科研通管家采纳,获得10
4秒前
5秒前
铜锣烧完成签到 ,获得积分10
6秒前
giegie6996完成签到 ,获得积分10
6秒前
小心胖虎发布了新的文献求助10
8秒前
乐乐应助tom采纳,获得10
9秒前
11秒前
12秒前
liu完成签到,获得积分10
12秒前
碧溪水完成签到,获得积分10
14秒前
echo完成签到,获得积分10
14秒前
wanyj发布了新的文献求助10
17秒前
222发布了新的文献求助10
18秒前
wshwx完成签到 ,获得积分10
24秒前
若水完成签到,获得积分10
24秒前
自然的衫完成签到 ,获得积分0
26秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
卤化钙钛矿人工突触的研究 2000
Моделирование процессов самоорганизации в кристаллообразующих системах 1000
History of U.S. Space Surveillance and Satellite Cataloging 1000
Signals, Systems, and Signal Processing 610
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6516135
求助须知:如何正确求助?哪些是违规求助? 8309144
关于积分的说明 17760222
捐赠科研通 5618380
什么是DOI,文献DOI怎么找? 2925328
邀请新用户注册赠送积分活动 1902409
关于科研通互助平台的介绍 1763529